SLDB
Solid Biosciences Inc.
Biotechnology · Healthcare · United States
6.20
close · 2026-10-30
value
38
cheaper than peers38
quality
49
stronger fundamentals49
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.74× | 62 |
| cash flow yield, 1 year ago | -15.1% | 52 |
| cash flow yield, 2 years ago | -14.4% | 50 |
| cash flow yield, 3 years ago | -15.2% | 49 |
| earnings yield, latest year | -32.1% | 46 |
| cash flow yield, latest year | -23.7% | 42 |
| earnings yield, 1 year ago | -49.4% | 39 |
| earnings yield, 2 years ago | -77.9% | 38 |
| earnings yield, 3 years ago | -162.9% | 25 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -65.5% | 51 |
| operating margin | 0.0% | 50 |
| debt to equity | 5.4% | 49 |
3 of 4 measures available
Facts
| market cap | $665M |
| free cash flow | -$118.2M |
| employees | 121 |
| first trade | 2018-01-26 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.99 | -3.06 | -4.83 | -10.10 |
| free cash flow | -$157.4M | -$100.7M | -$95.7M | -$101.0M |
| net income | -$174.3M | -$124.7M | -$96.0M | -$86.0M |
| revenue | $0 | $0 | $0 | $8.1M |
| unusual items | -$6.0M | -$4.8M | $63,000 | $11.1M |